APIMEDS PHARMACEUTICALS US INC Financials
Financial Health Signals
APIMEDS PHARMACEUTICALS US INC passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, APIMEDS PHARMACEUTICALS US INC generates $0.53 in operating cash flow (-$734K OCF vs -$1.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
APIMEDS PHARMACEUTICALS US INC earns $-10.8 in operating income for every $1 of interest expense (-$1.3M vs $118K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
This page shows APIMEDS PHARMACEUTICALS US INC (APUS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
APIMEDS PHARMACEUTICALS US INC reported -$1.4M in net income in fiscal year 2024. This represents a decrease of 78.7% from the prior year.
APIMEDS PHARMACEUTICALS US INC earned $-0.18 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 5.9% from the prior year.
APIMEDS PHARMACEUTICALS US INC held $3K in cash against $0 in long-term debt as of fiscal year 2024.
APIMEDS PHARMACEUTICALS US INC had 8M shares outstanding in fiscal year 2024. This represents an increase of 0.0% from the prior year.
APUS Income Statement
| Metric | Q3'25 | Q3'24 | Q4'23 |
|---|---|---|---|
| Revenue | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A |
| R&D Expenses | $620K | N/A | N/A |
| SG&A Expenses | $1.2M+308.2% | $300K | N/A |
| Operating Income | -$1.8M-514.7% | -$300K | N/A |
| Interest Expense | $6K-80.7% | $33K | N/A |
| Income Tax | N/A | N/A | N/A |
| Net Income | -$1.8M-435.7% | -$333K | N/A |
| EPS (Diluted) | $-0.14-250.0% | $-0.04 | N/A |
APUS Balance Sheet
| Metric | Q3'25 | Q3'24 | Q4'23 |
|---|---|---|---|
| Total Assets | $9.3M+70743.5% | $13K-96.9% | $422K |
| Current Assets | $9.1M+69488.0% | $13K-96.9% | $422K |
| Cash & Equivalents | $7.0M+202117.6% | $3K-99.2% | $410K |
| Inventory | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A |
| Total Liabilities | $1.1M-20.6% | $1.4M+251.4% | $390K |
| Current Liabilities | $1.1M+6.4% | $1.0M+730.7% | $123K |
| Long-Term Debt | N/A | N/A | N/A |
| Total Equity | $8.2M+700.9% | -$1.4M-4361.6% | $32K |
| Retained Earnings | -$9.2M-110.3% | -$4.4M-46.3% | -$3.0M |
APUS Cash Flow Statement
| Metric | Q3'25 | Q3'24 | Q4'23 |
|---|---|---|---|
| Operating Cash Flow | -$1.7M-1632.8% | -$100K | N/A |
| Capital Expenditures | $23K | N/A | N/A |
| Free Cash Flow | -$1.7M | N/A | N/A |
| Investing Cash Flow | -$23K | N/A | N/A |
| Financing Cash Flow | $0-100.0% | $77K | N/A |
| Dividends Paid | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A |
APUS Financial Ratios
| Metric | Q3'25 | Q3'24 | Q4'23 |
|---|---|---|---|
| Gross Margin | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A |
| Return on Assets | -19.3% | N/A | N/A |
| Current Ratio | 8.34+8.3 | 0.01-3.4 | 3.42 |
| Debt-to-Equity | 0.13+1.1 | -1.01-13.3 | 12.24 |
| FCF Margin | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$1.4M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.01), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
Is APIMEDS PHARMACEUTICALS US INC profitable?
No, APIMEDS PHARMACEUTICALS US INC (APUS) reported a net income of -$1.4M in fiscal year 2024.
What is APIMEDS PHARMACEUTICALS US INC's earnings per share (EPS)?
APIMEDS PHARMACEUTICALS US INC (APUS) reported diluted earnings per share of $-0.18 for fiscal year 2024. This represents a -5.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is APIMEDS PHARMACEUTICALS US INC's operating cash flow?
APIMEDS PHARMACEUTICALS US INC (APUS) generated -$734K in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are APIMEDS PHARMACEUTICALS US INC's total assets?
APIMEDS PHARMACEUTICALS US INC (APUS) had $13K in total assets as of fiscal year 2024, including both current and long-term assets.
How many shares does APIMEDS PHARMACEUTICALS US INC have outstanding?
APIMEDS PHARMACEUTICALS US INC (APUS) had 8M shares outstanding as of fiscal year 2024.
What is APIMEDS PHARMACEUTICALS US INC's current ratio?
APIMEDS PHARMACEUTICALS US INC (APUS) had a current ratio of 0.01 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is APIMEDS PHARMACEUTICALS US INC's debt-to-equity ratio?
APIMEDS PHARMACEUTICALS US INC (APUS) had a debt-to-equity ratio of -1.01 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is APIMEDS PHARMACEUTICALS US INC's return on assets (ROA)?
APIMEDS PHARMACEUTICALS US INC (APUS) had a return on assets of -10645.5% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is APIMEDS PHARMACEUTICALS US INC's cash runway?
Based on fiscal year 2024 data, APIMEDS PHARMACEUTICALS US INC (APUS) had $3K in cash against an annual operating cash burn of $734K. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is APIMEDS PHARMACEUTICALS US INC's debt-to-equity ratio negative or unusual?
APIMEDS PHARMACEUTICALS US INC (APUS) has negative shareholder equity of -$1.4M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is APIMEDS PHARMACEUTICALS US INC's Piotroski F-Score?
APIMEDS PHARMACEUTICALS US INC (APUS) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are APIMEDS PHARMACEUTICALS US INC's earnings high quality?
APIMEDS PHARMACEUTICALS US INC (APUS) has an earnings quality ratio of 0.53x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can APIMEDS PHARMACEUTICALS US INC cover its interest payments?
APIMEDS PHARMACEUTICALS US INC (APUS) has an interest coverage ratio of -10.8x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.